Edition:
India

Eiger BioPharmaceuticals Inc (EIGR.OQ)

EIGR.OQ on NASDAQ Stock Exchange Global Market

10.85USD
17 Nov 2017
Change (% chg)

$-0.05 (-0.46%)
Prev Close
$10.90
Open
$10.80
Day's High
$10.95
Day's Low
$10.45
Volume
11,138
Avg. Vol
18,885
52-wk High
$13.95
52-wk Low
$6.15

Summary

Name Age Since Current Position

David Cory

52 2016 President, Chief Executive Officer, Director

James Welch

58 2016 Chief Financial Officer

Rebecque Laba

53 2015 Vice President - Corporate Operations

Jeffrey Rudy

53 2006 Vice President - Clinical Operations

Ryan Takeya

46 2012 Vice President - Manufacturing

James Shaffer

49 2016 Chief Business Officer

David Apelian

51 2017 Director

Charles Bramlage

2016 Director

Thomas Dietz

2016 Director

Jeffrey Glenn

2016 Director

Evan Loh

2017 Director

Patrick Yang

69 2014 Director

Biographies

Name Description

David Cory

Mr. David A. Cory is President, Chief Executive Officer, Director of the Company. He has been the President and Chief Executive Officer of Eiger since 2009. Prior to working at Eiger, Mr. Cory was Chief Executive Officer of DiObex from 2007 to 2008 and President and Chief Operating Officer at Prestwick Pharmaceuticals from 2004 to 2006. Mr. Cory was Co-Founder and Acting Chief Commercial Officer at CoTherix in 2003 and Senior Vice President of Sales and Marketing at InterMune from 2000 to 2003. Previously, Mr. Cory held positions of increasing responsibility in Commercial Operations at Glaxo, Glaxo Wellcome, and Glaxo Smith Kline. Mr. Cory earned a B.S. in Pharmacy from the University of Cincinnati, College of Pharmacy and an M.B.A. from the University of Maryland University College.

James Welch

Mr. James H. Welch is Chief Financial Officer of the Company. Mr. Welch has over 20 years of experience as Chief Financial Officer at both public and private companies including at Virobay Inc. from 2014 to 2015, at AcelRx Pharmaceuticals, Inc. from 2010 to 2014, at Cerimon Pharmaceuticals, Inc. from 2006 to 2010, at Rigel Pharmaceuticals, Inc. from 1999 to 2006, and at Biocircuits Corporation from 1992 to 1998. Mr. Welch graduated from Whitworth College with a B.A. in Business Administration and from Washington State University with an M.B.A. in Finance.

Rebecque Laba

Ms. Rebecque J. Laba is Vice President - Corporate Operations of Company. she has served as our Vice President, Corporate Operations since January 2015 and served as our Vice President of Finance and Administration from September 2007 to January 2015. Previously, she served as a consultant to us on finance and administrative matters since October 2005. From 1999 to 2005, Ms. Laba served in various financial and operational roles at Idun Pharmaceuticals, Inc. until Idun was acquired by Pfizer Inc., a pharmaceutical company, in 2005. From 1997 to 1999, Ms. Laba worked at Asset Management Group, where she served in various financial and operational roles.

Jeffrey Rudy

Mr. Jeffrey J. Rudy is the Vice President, Clinical Operations of Celladon Corporation. From 1997 to 2006, Mr. Rudy worked at Agouron Pharmaceuticals (prior to its acquisition by the Warner-Lambert Company, which was subsequently acquired by Pfizer) where he served in roles of increasing responsibility within its clinical research operations, including portfolio manager of the ophthalmology franchise and director of development operations. From 1995 to 1997, Mr. Rudy was at Gilead Sciences, Inc., a biopharmaceutical company, where he was clinical program manager in the clinical research department overseeing a number of antiviral compounds in early development. From 1991 to 1994, Mr. Rudy was at Amgen, where he worked in clinical affairs on a number of antiviral programs. Mr. Rudy received his B.S. in Microbiology from Ohio State University.

Ryan Takeya

Mr. Ryan K. Takeya is Vice President - Manufacturing of Celladon Corp. Previously, Mr. Takeya served as a biotechnology process development and manufacturing consultant from 2010 until April 2012, other than during 2011 when he was employed by Dendreon Corporation, a biotechnology company, where he was involved with the transfer of the PROVENGE antigen manufacturing process to a secondary commercial manufacturing site. From August 1996 to December 2009, Mr. Takeya served in the Manufacturing Group at Targeted Genetics Corporation, a biotechnology company, where he oversaw in-house and contract manufacturing of clinical gene therapy products, including clinical supplies used in the MYDICAR clinical program. From 1993 to 1996, Mr. Takeya held various process development and process transfer roles at Immunex Corporation, a biotechnology company. Mr. Takeya received his B.A. in Chemistry from the University of Washington.

James Shaffer

Mr. James P. Shaffer is Chief Business Officer of the Company. Mr. Shaffer was Vice President and Chief Commercial Officer at Halozyme Therapeutics from 2011 to 2014 and Executive Vice President and Chief Commercial Officer at Clinical Data Inc. from 2007 to 2011. Prior to those positions, Mr. Shaffer held a series of different sale and product related positions of increasing responsibility at multiple pharmaceutical companies. Mr. Shaffer earned a B.S. in Agriculture Economics and an M.B.A. from the Ohio State University.

David Apelian

Dr. David Apelian M.D. Ph.D. is the Director of the company. Dr. Apelian is currently Executive VP and Chief Medical Officer of Achillion Pharmaceuticals, Inc. a position he has held since 2013. At Achillion, he was responsible for creating portfolio strategy and managing the company's clinical development programs with a focus on hepatitis C. He was instrumental in securing a partnership between Achillion and J&J, which resulted in a$225 millionequity upfront payment and the potential for over$900 millionin milestones. Currently, he is leading the Achillion rare disease development program for novel small-molecule complement factor D inhibitors for alternative pathway-mediated diseases. From 2005 to 2013. Dr. Apelian was Chief Medical Officer and subsequently head of all R&D and Regulatory Affairs for GlobeImmune, where he was a member of the management team that built the company to include multiple immuno-oncology and infectious disease programs, as well as helping to secure multiple corporate and government partnerships. He was previously at Bristol-Myers Squibb where he served as Clinical Director in the Department of Clinical Design and Evaluation/Infectious Diseases Group and was Medical Leader for clinical development for Baraclude (entecavir) for chronic HBV through NDA filing. Baraclude is widely recognized as one of the most successful antiviral therapies, with revenues exceeding$1 billionper year. Prior to that, Dr. Apelian was Clinical Director in the Department of Hepatology & Gastroenterology at Schering Plough, where he coordinated a supplemental NDA filing for interferon alpha-2b and ribavirin for the treatment of pediatric patients with chronic HCV. He received a PhD in Biochemistry fromRutgers University, an MD from theUniversity of Medicine and Dentistry of New Jerseyand an MBA fromQuinnipiac University. He earned a BA in Biochemistry from Rutgers University.

Charles Bramlage

Thomas Dietz

Jeffrey Glenn

Evan Loh

Dr. Evan Loh, M.D., is Director of the Company. Dr. Loh, MD, is President, Chief Operating Officer and Chief Medical Officer, as well as a member of the Board of Directors at Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK). Prior to Paratek's merger with Transcept Pharmaceuticals, Dr. Loh served as Paratek's Executive Chairman of the Board of Directors fromJune 2012toJune 2014. Previously, Dr. Loh served as Senior Vice President, Development and Strategic Operations, Worldwide Research and Development, at Pfizer. While at Pfizer, Dr. Loh's responsibilities included scientific, operational, and strategic drug development oversight for all pre-proof of concept development phase programs and leading portfolio prioritization. Dr. Loh joined Pfizer from Wyeth Pharmaceuticals, where he was Vice President, Multiple Therapeutic Areas, where he was responsible for global development strategy and clinical operational deliverables, including leading the successful global registration programs for Torisel ® and Tygacil ® . Dr. Loh served as a faculty member at both Harvard Medical School and the University of Pennsylvania, School of Medicine. Dr. Loh received his A.B. from Harvard College and his M.D. from Harvard Medical School. He completed his Internal Medicine and Cardiovascular fellowship training at Brigham and Women's Hospital in Boston, MA.

Patrick Yang

Dr. Patrick Y. Yang, Ph.D., is Director of Celladon Corporation. Patrick Y. Yang, Ph.D., 67, has served on our Board of Directors since March 2014. Dr. Yang recently retired from F. Hoffman-La Roche AG, a global pharmaceutical and diagnostics company, where he served as Executive Vice President and Global Head of Pharmaceutical Technical Operations from January 2010 until March 2013. In this role, Dr. Yang was responsible for Roche’s pharmaceutical and biotechnology manufacturing operations, process development, quality, regulatory, supply management, distribution, and procurement functions, based in Switzerland. From December 2003 through December 2009, Dr. Yang worked for Genentech, Inc., a leading biotechnology company, where his most recent position was Executive Vice President of Product Operations responsible for Genentech’s manufacturing, engineering, process development, regulatory, quality, compliance, and supply chain management functions. Prior to Genentech, Dr. Yang held several leadership roles at Merck, including Vice President of Asia/Pacific Operations and Vice President of Supply Chain Management. He also previously worked at General Electric Co. and Life Systems, Inc. in research, development, and manufacturing operations. Dr. Yang currently works as a biotech industry consultant. He serves on the board of directors of Tesoro Corporation, a publicly held company in the business of refining and marketing petroleum products, the board of directors of Codexis, Inc., a publicly held company in the development and production of custom industrial enzymes for use in the pharmaceutical, chemical and biofuel production; and on the board of directors of Amyris, Inc., a synthetic biology company. Dr. Yang holds a Ph.D. in engineering from Ohio State University. Our Nominating and Corporate Governance Committee believes that Dr. Yang’s expertise and experience in the pharmaceutical and biotechnology industries qualifies him to serve on our Board of Directors.